Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease.
The last decade has seen exciting advances in the development of potential stem cell-based therapies for Parkinson's disease (PD), which have used different types of stem cells as starting material. These cells have been developed primarily to replace dopamine-producing neurons in the substantia nigra that are progressively lost in the disease process. The aim is to largely restore lost motor functions, whilst not ever being curative. We discuss cell-based strategies that will have to fulfill important criteria to become effective and competitive therapies for PD. These criteria include reproducibly producing sufficient numbers of cells with an authentic substantia nigra dopamine neuron A9 phenotype, which can integrate into the host brain after transplantation and form synapses (considered crucial for long-term functional benefits). Furthermore, it is essential that transplanted cells exhibit no, or only very low levels of, proliferation without tumor formation at the site of grafting. Cumulative research has shown that stem cell-based approaches continue to have great potential in PD, but key questions remain to be answered. Here, we review the most recent progress in research on stem cell-based dopamine neuron replacement therapy for PD and briefly discuss what the immediate future might hold. © 2021 International Parkinson and Movement Disorder Society.
['Barbuti|Peter A|PA|0000-0001-9182-1629', 'Barker|Roger A|RA|0000-0001-8843-7730', 'Brundin|Patrik|P|0000-0003-2924-5186', 'Przedborski|Serge|S|', 'Papa|Stella M|SM|0000-0003-3010-6343', 'Kalia|Lorraine V|LV|0000-0002-9384-1305', 'Mochizuki|Hideki|H|0000-0002-0874-7542', '|||']
D004298:Dopamine D059290:Dopaminergic Neurons D006801:Humans D010300:Parkinson Disease D033581:Stem Cell Transplantation D013378:Substantia Nigra
dopaminergic neurons Parkinson's disease stem cells iPSCs ESC